CAFC again reverses Lialda patent ruling, remands case

The U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed its previous decision to reverse a district court ruling that Actavis plc (NYSE:ACT) infringed on a patent for ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG). The CAFC remanded the case to the U.S. District Court for the Southern District of Florida.

Shire alleged Actavis' ANDA for generic Lialda infringed on Shire's U.S. Patent No. 6,773,720, which expires in 2020. The district court ruled in Shire's favor in May 2013. In 2014, the CAFC reviewed the facts of the case and overturned the district court's ruling. ...